Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 257 articles:
HTML format
Text format



Single Articles


    July 2018
  1. BAXA J, Matouskova T, Ludvik J, Sedlmair M, et al
    Single-source Dual-energy CT as a Part of (18)F-FDG PET/CT: Direct Comparison of Iodine-related and Metabolic Parameters in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4131-4137.
    PubMed     Text format     Abstract available


  2. SCHMID S, Csanadi A, Kozhuharov N, Tchudjin M, et al
    CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3913-3918.
    PubMed     Text format     Abstract available


  3. MAIUTHED A, Chantarawong W, Chanvorachote P
    Lung Cancer Stem Cells and Cancer Stem Cell-targeting Natural Compounds.
    Anticancer Res. 2018;38:3797-3809.
    PubMed     Text format     Abstract available


    June 2018
  4. TAKEOKA H, Yamada K, Naito Y, Matsuo N, et al
    Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
    Anticancer Res. 2018;38:3779-3784.
    PubMed     Text format     Abstract available


  5. SHOJI F, Yamazaki K, Miura N, Katsura M, et al
    Postoperative Management of Multiple Primary Cancers Associated with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3773-3778.
    PubMed     Text format     Abstract available


  6. SYRIGOS KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, et al
    Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study.
    Anticancer Res. 2018;38:3735-3744.
    PubMed     Text format     Abstract available


  7. TAKAMORI S, Toyokawa G, Shimokawa M, Kinoshita F, et al
    Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation.
    Anticancer Res. 2018;38:3731-3734.
    PubMed     Text format     Abstract available


  8. TOYOKAWA G, Takada K, Tagawa T, Kinoshita F, et al
    Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.
    Anticancer Res. 2018;38:3707-3711.
    PubMed     Text format     Abstract available


  9. BANNA GL, Camerini A, Bronte G, Anile G, et al
    Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.
    Anticancer Res. 2018;38:3689-3697.
    PubMed     Text format     Abstract available


  10. MATSUMOTO T, Hasebe T, Baba Y, Chosa K, et al
    Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3587-3592.
    PubMed     Text format     Abstract available


  11. RAUNGRUT P, Wongkotsila A, Champoochana N, Lirdprapamongkol K, et al
    Knockdown of 14-3-3gamma Suppresses Epithelial-Mesenchymal Transition and Reduces Metastatic Potential of Human Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:3507-3514.
    PubMed     Text format     Abstract available


  12. KOYI H, Branden E, Kasim I, Wilander E, et al
    Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3341-3346.
    PubMed     Text format     Abstract available


  13. LAI JZ, Lai HH, Cao D
    Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.
    Anticancer Res. 2018;38:3757-3761.
    PubMed     Text format     Abstract available


  14. HAGI T, Nakamura T, Sugino Y, Matsubara T, et al
    Is FDG-PET/CT Useful for Diagnosing Pulmonary Metastasis in Patients with Soft Tissue Sarcoma?
    Anticancer Res. 2018;38:3635-3639.
    PubMed     Text format     Abstract available


  15. MASUHIRO K, Shiroyama T, Suzuki H, Takata SO, et al
    Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M.
    Anticancer Res. 2018;38:3567-3571.
    PubMed     Text format     Abstract available


  16. KOMIYA K, Nakashima C, Nakamura T, Hirakawa H, et al
    Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy.
    Anticancer Res. 2018;38:3559-3566.
    PubMed     Text format     Abstract available


  17. LIN MX, Lin SH, Lin CC, Yang CC, et al
    In Vitro and In Vivo Antitumor Effects of Pyrimethamine on Non-small Cell Lung Cancers.
    Anticancer Res. 2018;38:3435-3445.
    PubMed     Text format     Abstract available


  18. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Text format     Abstract available


    May 2018
  19. SHINOHARA S, Sugaya M, Onitsuka T, Machida K, et al
    Prognostic Impact of Postoperative C-reactive Protein for Non-small Cell Lung Cancer Following Lobectomy.
    Anticancer Res. 2018;38:3193-3198.
    PubMed     Text format     Abstract available


  20. KINOSHITA F, Toyokawa G, Tagawa T, Matsubara T, et al
    Takotsubo Cardiomyopathy Developed After Two-stage Surgery for Double Primary Lung Cancer.
    Anticancer Res. 2018;38:2957-2960.
    PubMed     Text format     Abstract available


  21. ALMQUIST D, Khanal N, Smith L, Ganti AK, et al
    Preoperative Pulmonary Function Tests (PFTs) and Outcomes from Resected Early Stage Non-small Cell Lung Cancer (NSCLC).
    Anticancer Res. 2018;38:2903-2907.
    PubMed     Text format     Abstract available


  22. LIAO TY, Liaw CC, Tsui KH, Juan YH, et al
    Renal Pelvis Carcinoma with Renal Vein or Inferior Vena Cava Involvement Linked to Early-onset Lung Metastasis Based on CT Scan Diagnosis.
    Anticancer Res. 2018;38:3187-3192.
    PubMed     Text format     Abstract available


  23. KABURAGI T, Kiyoshima M, Nawa T, Ichimura H, et al
    Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.
    Anticancer Res. 2018;38:3145-3150.
    PubMed     Text format     Abstract available


  24. KAWAGUCHI Y, Okano T, Kakihana M, Kajiwara N, et al
    Transition Rate from EGFR-TKI to Cytotoxic Chemotherapy Patients with EGFR Mutation-positive Lung Adenocarcinoma.
    Anticancer Res. 2018;38:3127-3132.
    PubMed     Text format     Abstract available


  25. TANAKA K, Toyokawa G, Tagawa T, Ijichi K, et al
    Successful Treatment of Growing Teratoma Syndrome of the Lung by Surgical Resection: A Case Report and Literature Review.
    Anticancer Res. 2018;38:3115-3118.
    PubMed     Text format     Abstract available


  26. OHNO T, Kubouchi Y, Wakahara M, Nosaka K, et al
    Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma.
    Anticancer Res. 2018;38:3001-3007.
    PubMed     Text format     Abstract available


    April 2018
  27. TAKEMURA Y, Chihara Y, Morimoto Y, Tanimura K, et al
    Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2385-2390.
    PubMed     Text format     Abstract available


  28. LUND-IVERSEN M, Scott H, Strom EH, Theiss N, et al
    Expression of Estrogen Receptor-alpha and Survival in Advanced-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2261-2269.
    PubMed     Text format     Abstract available


  29. VO VTA, Choi JW, Phan ANH, Hua TNM, et al
    TRAP1 Inhibition Increases Glutamine Synthetase Activity in Glutamine Auxotrophic Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:2187-2193.
    PubMed     Text format     Abstract available


  30. CHEN WT, Chen YK, Lin SS, Hsu FT, et al
    Hyperforin Suppresses Tumor Growth and NF-kappaB-mediated Anti-apoptotic and Invasive Potential of Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2161-2167.
    PubMed     Text format     Abstract available


  31. BIANCONI F, Fravolini ML, Bello-Cerezo R, Minestrini M, et al
    Evaluation of Shape and Textural Features from CT as Prognostic Biomarkers in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2155-2160.
    PubMed     Text format     Abstract available


  32. HSIA TC, Huang YP, Jiang YW, Chen HY, et al
    Phenethyl Isothiocyanate Induces Apoptotic Cell Death Through the Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro.
    Anticancer Res. 2018;38:2137-2147.
    PubMed     Text format     Abstract available


  33. KANAJI N, Yokohira M, Watanabe N, Kadowaki N, et al
    Transforming Growth Factor-Beta Produced by Non-small Cell Lung Cancer Cells Contributes to Lung Fibroblast Contractile Phenotype.
    Anticancer Res. 2018;38:2007-2014.
    PubMed     Text format     Abstract available


  34. MATSUMOTO N, Kumasaka A, Ando T, Komiyama K, et al
    Detection of EGFR Gene Mutation by Mutation-oriented LAMP Method.
    Anticancer Res. 2018;38:2093-2099.
    PubMed     Text format     Abstract available


  35. RZECHONEK A, Grzegrzolka J, Blasiak P, Ornat M, et al
    Correlation of Expression of Tenascin C and Blood Vessel Density in Non-small Cell Lung Cancers.
    Anticancer Res. 2018;38:1987-1991.
    PubMed     Text format     Abstract available


  36. SATAKE T, Suetsugu A, Nakamura M, Hasegawa K, et al
    Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.
    Anticancer Res. 2018;38:1927-1935.
    PubMed     Text format     Abstract available


    March 2018
  37. TOYOKAWA G, Yamada Y, Tagawa T, Kinoshita F, et al
    High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer.
    Anticancer Res. 2018;38:1821-1825.
    PubMed     Text format     Abstract available


  38. NASU S, Suzuki H, Shiroyama T, Tanaka A, et al
    Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
    Anticancer Res. 2018;38:1783-1788.
    PubMed     Text format     Abstract available


  39. MATSUBARA T, Toyokawa G, Kinoshita F, Haratake N, et al
    Safety of Simultaneous Bilateral Pulmonary Resection for Metastatic Lung Tumors.
    Anticancer Res. 2018;38:1715-1719.
    PubMed     Text format     Abstract available


  40. SATO Y, Fujimoto D, Uehara K, Kawachi H, et al
    Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections.
    Anticancer Res. 2018;38:1401-1405.
    PubMed     Text format     Abstract available


    February 2018
  41. KATO Y, Kashima J, Watanabe K, Yomota M, et al
    Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:1077-1083.
    PubMed     Text format     Abstract available


  42. HORTON CE, Kamal M, Leslie M, Zhang R, et al
    Circulating Tumor Cells Accurately Predicting Progressive Disease After Treatment in a Patient with Non-small Cell Lung Cancer Showing Response on Scans.
    Anticancer Res. 2018;38:1073-1076.
    PubMed     Text format     Abstract available


  43. SAITOH JI, Shirai K, Abe T, Kubo N, et al
    A Phase I Study of Hypofractionated Carbon-ion Radiotherapy for Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:885-891.
    PubMed     Text format     Abstract available


  44. VALAN CD, Slagsvold JE, Halvorsen TO, Herje M, et al
    Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.
    Anticancer Res. 2018;38:871-876.
    PubMed     Text format     Abstract available


  45. GLATZEL-PLUCINSKA N, Piotrowska A, Grzegrzolka J, Olbromski M, et al
    SATB1 Level Correlates with Ki-67 Expression and Is a Positive Prognostic Factor in Non-small Cell Lung Carcinoma.
    Anticancer Res. 2018;38:723-736.
    PubMed     Text format     Abstract available


  46. KOH YW, Park SY, Hyun SH, Lee SJ, et al
    Associations Between PET Textural Features and GLUT1 Expression, and the Prognostic Significance of Textural Features in Lung Adenocarcinoma.
    Anticancer Res. 2018;38:1067-1071.
    PubMed     Text format     Abstract available


  47. HIRAI F, Kinoshita I, Matsubara T, Haratake N, et al
    Which Primary Organ Is Most Suitable for Performing Pulmonary Metastasectomy?
    Anticancer Res. 2018;38:1041-1045.
    PubMed     Text format     Abstract available


  48. ROBELLA M, Vaira M, Borsano A, Mossetti C, et al
    Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei.
    Anticancer Res. 2018;38:929-932.
    PubMed     Text format     Abstract available


  49. KOBAYASHI K, Seike M, Zou F, Noro R, et al
    Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
    Anticancer Res. 2018;38:753-762.
    PubMed     Text format     Abstract available


  50. AKIMOTO J, Nakayama M, Takagi S, Okano T, et al
    Improved In Vivo Subcutaneous Tumor Generation by Cancer Cell Sheet Transplantation.
    Anticancer Res. 2018;38:671-676.
    PubMed     Text format     Abstract available


  51. NIEDER C, Kampe TA, Engljahringer K
    Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
    Anticancer Res. 2018;38:901-904.
    PubMed     Text format     Abstract available


    January 2018
  52. KATAOKA Y, Hirano K, Narabayashi T, Hara S, et al
    Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:559-563.
    PubMed     Text format     Abstract available


  53. TAKAMORI S, Toyokawa G, Okamoto I, Takada K, et al
    Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:553-557.
    PubMed     Text format     Abstract available


  54. SLUGA R, VAN DEN Borne BEEM, Roepman P, Peters BJM, et al
    Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
    Anticancer Res. 2018;38:393-400.
    PubMed     Text format     Abstract available


  55. JUNG CY, Kim SY, Lee C
    Carvacrol Targets AXL to Inhibit Cell Proliferation and Migration in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:279-286.
    PubMed     Text format     Abstract available


  56. SHEN TC, Chang WS, Tsai CW, Chao CY, et al
    The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes in Taiwan Lung Cancer Risk.
    Anticancer Res. 2018;38:253-257.
    PubMed     Text format     Abstract available


  57. FANG T, Huang H, Li X, Liao J, et al
    Effects of siRNA Silencing of TUG1 and LCAL6 Long Non-coding RNAs on Patient-derived Xenograft of Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:179-186.
    PubMed     Text format     Abstract available


  58. DAMASKOS C, Tomos I, Garmpis N, Karakatsani A, et al
    Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
    Anticancer Res. 2018;38:37-43.
    PubMed     Text format     Abstract available


  59. PRECIVAL C, Landy M, Poole C, Mullaney L, et al
    The Role of Prophylactic Cranial Irradiation for Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:7-14.
    PubMed     Text format     Abstract available


  60. HIGUCHI T, Yamamoto N, Hayashi K, Takeuchi A, et al
    The Efficacy of Wide Resection for Musculoskeletal Metastatic Lesions of Renal Cell Carcinoma.
    Anticancer Res. 2018;38:577-582.
    PubMed     Text format     Abstract available


    December 2017
  61. TAKADA K, Toyokawa G, Tagawa T, Kohashi K, et al
    Association Between PD-L1 Expression and Metabolic Activity on (18)F-FDG PET/CT in Patients with Small-sized Lung Cancer.
    Anticancer Res. 2017;37:7073-7082.
    PubMed     Text format     Abstract available


  62. SHOJI F, Matsubara T, Kozuma Y, Haratake N, et al
    Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6997-7003.
    PubMed     Text format     Abstract available


  63. KULDA V, Hrda K, Houdek Z, Dobra JK, et al
    Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6953-6958.
    PubMed     Text format     Abstract available


  64. ERBER R, Stohr R, Herlein S, Giedl C, et al
    Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer(R) Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6771-6778.
    PubMed     Text format     Abstract available


  65. MATSUBARA T, Toyokawa G, Yamada Y, Nabeshima K, et al
    A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis.
    Anticancer Res. 2017;37:6937-6941.
    PubMed     Text format     Abstract available


    November 2017
  66. OYA Y, Yoshida T, Kuroda H, Shimizu J, et al
    Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.
    Anticancer Res. 2017;37:6477-6480.
    PubMed     Text format     Abstract available


  67. WILLS B, Cardona AF, Rojas L, Ruiz-Patino A, et al
    Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
    Anticancer Res. 2017;37:6429-6436.
    PubMed     Text format     Abstract available


  68. TUNGSUKRUTHAI S, Sritularak B, Chanvorachote P
    Cycloartobiloxanthone Inhibits Migration and Invasion of Lung Cancer Cells.
    Anticancer Res. 2017;37:6311-6319.
    PubMed     Text format     Abstract available


  69. PINKHIEN T, Petpiroon N, Sritularak B, Chanvorachote P, et al
    Batatasin III Inhibits Migration of Human Lung Cancer Cells by Suppressing Epithelial to Mesenchymal Transition and FAK-AKT Signals.
    Anticancer Res. 2017;37:6281-6289.
    PubMed     Text format     Abstract available


  70. MAIUTHED A, Pinkhien T, Chamni S, Suwanborirux K, et al
    Apoptosis-inducing Effect of Hydroquinone 5-O-Cinnamoyl Ester Analog of Renieramycin M on Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:6259-6267.
    PubMed     Text format     Abstract available


  71. ICHIHARA H, Kuwabara K, Matsumoto Y
    Trehalose Liposomes Suppress the Growth of Tumors on Human Lung Carcinoma-bearing Mice by Induction of Apoptosis In Vivo.
    Anticancer Res. 2017;37:6133-6139.
    PubMed     Text format     Abstract available


  72. MORIN C, Fortin S
    Docosahexaenoic Acid Monoglyceride Increases Carboplatin Activity in Lung Cancer Models by Targeting EGFR.
    Anticancer Res. 2017;37:6015-6023.
    PubMed     Text format     Abstract available


  73. FIALA O, Hosek P, Pesek M, Finek J, et al
    Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.
    Anticancer Res. 2017;37:6469-6476.
    PubMed     Text format     Abstract available


  74. MULLER L, Radtke A, Decker J, Koch M, et al
    The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines.
    Anticancer Res. 2017;37:6341-6345.
    PubMed     Text format     Abstract available


  75. SANOMACHI T, Suzuki S, Kuramoto K, Takeda H, et al
    Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.
    Anticancer Res. 2017;37:6177-6188.
    PubMed     Text format     Abstract available


    October 2017
  76. SHOJI F, Yamashita N, Inoue Y, Kozuma Y, et al
    Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients.
    Anticancer Res. 2017;37:5871-5876.
    PubMed     Text format     Abstract available


  77. TANIGUCHI Y, Tamiya A, Isa SI, Nakahama K, et al
    Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.
    Anticancer Res. 2017;37:5857-5862.
    PubMed     Text format     Abstract available


  78. MATSUMOTO Y, Ohara S, Furukawa R, Usui K, et al
    The Prognosis of Small Cell Lung Cancer in Patients with Pulmonary Fibrosis.
    Anticancer Res. 2017;37:5791-5795.
    PubMed     Text format     Abstract available


  79. TAKEUCHI A, Oguri T, Sone K, Ito K, et al
    Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Anticancer Res. 2017;37:5771-5776.
    PubMed     Text format     Abstract available


  80. SHIBA S, Saitoh JI, Irie D, Shirai K, et al
    Potential Pitfalls of a Fiducial Marker-matching Technique in Carbon-ion Radiotherapy for Lung Cancer.
    Anticancer Res. 2017;37:5673-5680.
    PubMed     Text format     Abstract available


  81. SUDO K, Sato K, Sakamoto S, Hasegawa Y, et al
    Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab.
    Anticancer Res. 2017;37:5565-5571.
    PubMed     Text format     Abstract available


  82. NAKAHAMA K, Isa SI, Tamiya A, Taniguchi Y, et al
    The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter.
    Anticancer Res. 2017;37:5885-5891.
    PubMed     Text format     Abstract available


  83. HARATAKE N, Toyokawa G, Tagawa T, Kozuma Y, et al
    Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
    Anticancer Res. 2017;37:5713-5717.
    PubMed     Text format     Abstract available


  84. YASUKAWA M, Kawaguchi T, Kawai N, Tojo T, et al
    Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases.
    Anticancer Res. 2017;37:5573-5576.
    PubMed     Text format     Abstract available


    September 2017
  85. CELIK E, Semrau R, Baues C, Trommer-Nestler M, et al
    Robot-assisted Extracranial Stereotactic Radiotherapy of Adrenal Metastases in Oligometastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:5285-5291.
    PubMed     Text format     Abstract available


  86. TAMIYA A, Tamiya M, Nakahama K, Taniguchi Y, et al
    Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:5199-5205.
    PubMed     Text format     Abstract available


  87. SHINTANI T, Matsuo Y, Iizuka Y, Mitsuyoshi T, et al
    Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy.
    Anticancer Res. 2017;37:5161-5167.
    PubMed     Text format     Abstract available


  88. SONE K, Oguri T, Ito K, Kitamura Y, et al
    Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2017;37:5125-5131.
    PubMed     Text format     Abstract available


  89. ONISHI H, Nakamura K, Nagai S, Yanai K, et al
    Hedgehog Inhibition Upregulates TRK Expression to Antagonize Tumor Suppression in Small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:4987-4992.
    PubMed     Text format     Abstract available


  90. HAMAGUCHI R, Okamoto T, Sato M, Hasegawa M, et al
    Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
    Anticancer Res. 2017;37:5141-5145.
    PubMed     Text format     Abstract available


  91. ANNEDE P, Darreon J, Benkemouche A, Valdenaire S, et al
    Flattening Filter Free vs. Flattened Beams for Lung Stereotactic Body Radiation Therapy.
    Anticancer Res. 2017;37:5133-5139.
    PubMed     Text format     Abstract available


  92. AMPIL F, Ellika S, Nanda A, Vora M, et al
    Long-term Survival After Stereotactic Radiosurgery of Brain Metastases: A Case Series with 10-year Follow-up.
    Anticancer Res. 2017;37:5113-5115.
    PubMed     Text format     Abstract available


  93. DIVELLA R, Daniele A, DE Luca R, Simone M, et al
    Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:4867-4871.
    PubMed     Text format     Abstract available


  94. TAKENAKA T, Katayama M, Sugiyama A, Hagiwara M, et al
    Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density.
    Anticancer Res. 2017;37:4779-4788.
    PubMed     Text format     Abstract available


    August 2017
  95. HE Q, Bi X, Ren C, Wang Y, et al
    Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases.
    Anticancer Res. 2017;37:4711-4716.
    PubMed     Text format     Abstract available


  96. WONG W, Sun P, Mu Z, Liu J, et al
    Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4687-4691.
    PubMed     Text format     Abstract available


  97. YANG Y, Sun N, Sun P, Zhang L, et al
    Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.
    Anticancer Res. 2017;37:4681-4686.
    PubMed     Text format     Abstract available


  98. WANG F, Lu J, Li S, Huo X, et al
    Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis.
    Anticancer Res. 2017;37:4515-4522.
    PubMed     Text format     Abstract available


  99. YANG F, Gu Y, Zhao Z, Huang J, et al
    NHERF1 Suppresses Lung Cancer Cell Migration by Regulation of Epithelial-Mesenchymal Transition.
    Anticancer Res. 2017;37:4405-4414.
    PubMed     Text format     Abstract available


  100. ZHAO Z, Cheng S, Zabkiewicz C, Chen J, et al
    Reduced Expression of RanBPM Is Associated with Poorer Survival from Lung Cancer and Increased Proliferation and Invasion of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:4389-4397.
    PubMed     Text format     Abstract available


  101. FLAMINI V, Jiang WG, Cui Y
    Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4319-4327.
    PubMed     Text format     Abstract available


  102. YU Z, Sanders AJ, Owen S, Cheng S, et al
    Expression of Osteoprotegrin Is Enhanced in Lung Cancer Tissues and Promotes Aggressive Cellular Traits in H3122 Lung Cancer Cells.
    Anticancer Res. 2017;37:4277-4283.
    PubMed     Text format     Abstract available


  103. TAKAMORI S, Toyokawa G, Okamoto I, Takada K, et al
    Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4223-4228.
    PubMed     Text format     Abstract available


  104. TAMIYA A, Tamiya M, Nishihara T, Shiroyama T, et al
    Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
    Anticancer Res. 2017;37:4177-4182.
    PubMed     Text format     Abstract available


  105. ARIYASU R, Horiike A, Yoshizawa T, Dotsu Y, et al
    Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.
    Anticancer Res. 2017;37:4229-4232.
    PubMed     Text format     Abstract available


    July 2017
  106. YOTSUMOTO F, Fukagawa S, Miyata K, Nam SO, et al
    HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFRT790M.
    Anticancer Res. 2017;37:3825-3831.
    PubMed     Text format     Abstract available


  107. NAKAO M, Muramatsu H, Kagawa Y, Suzuki Y, et al
    Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations.
    Anticancer Res. 2017;37:3781-3786.
    PubMed     Text format     Abstract available


  108. BANNA GL, Parra HJS, Castaing M, Dieci MV, et al
    Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:3723-3728.
    PubMed     Text format     Abstract available


  109. SHEN TC, Hsia TC, Chao CY, Chen WC, et al
    The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer.
    Anticancer Res. 2017;37:3563-3567.
    PubMed     Text format     Abstract available


  110. PANCEWICZ-WOJTKIEWICZ J, Bernatowicz PL
    The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:3543-3546.
    PubMed     Text format     Abstract available


  111. OTSUKA T, Nojiri T, Minami S, Hosoda H, et al
    Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin-Paclitaxel: A Prospective Study.
    Anticancer Res. 2017;37:3505-3512.
    PubMed     Text format     Abstract available


  112. KOBAYASHI H, Hamasaki M, Morishita T, Inoue T, et al
    Analysis of Evolving Clinicopathological Features of Metastatic Brain Tumors Over 30 Years of Surgical Management.
    Anticancer Res. 2017;37:3969-3974.
    PubMed     Text format     Abstract available


  113. MARIAMPILLAI AI, Cruz JPD, Suh J, Sivapiragasam A, et al
    Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries.
    Anticancer Res. 2017;37:3649-3656.
    PubMed     Text format     Abstract available


    June 2017
  114. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Outcomes of Non-small Cell Lung Cancer in Patients with a History of Pancreaticobiliary Cancer.
    Anticancer Res. 2017;37:3307-3309.
    PubMed     Text format     Abstract available


  115. NAKAMICHI S, Seike M, Miyanaga A, Chiba M, et al
    RT-PCR for Detecting ALK Translocations in Cytology Samples from Lung Cancer Patients.
    Anticancer Res. 2017;37:3295-3299.
    PubMed     Text format     Abstract available


  116. MUTO S, Takagi H, Owada Y, Inoue T, et al
    Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2017;37:3169-3174.
    PubMed     Text format     Abstract available


  117. WANG W, Zhong W, Chen C, Meng Q, et al
    Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
    Anticancer Res. 2017;37:3151-3155.
    PubMed     Text format     Abstract available


  118. SINAGRA E, Raimondo D, Gallo E, Stella M, et al
    JC Virus and Lung Adenocarcinoma: Fact or Myth?
    Anticancer Res. 2017;37:3311-3314.
    PubMed     Text format     Abstract available


  119. KADERBHAI C, Richard C, Fumet JD, Aarnink A, et al
    Antibiotic Use Does Not Appear to Influence Response to Nivolumab.
    Anticancer Res. 2017;37:3195-3200.
    PubMed     Text format     Abstract available


  120. MENCOBONI M, Filiberti RA, Taveggia P, Del Corso L, et al
    Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
    Anticancer Res. 2017;37:3189-3194.
    PubMed     Text format     Abstract available


  121. RIZZARDI C, Athanasakis E, Cammisuli F, Monego SD, et al
    Puzzling Results from BAP1 Germline Mutations Analysis in a Group of Asbestos-Exposed Patients in a High-risk Area of Northeast Italy.
    Anticancer Res. 2017;37:3073-3083.
    PubMed     Text format     Abstract available


    May 2017
  122. YOSHIDA H, Kim YH, Ozasa H, Nagai H, et al
    EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.
    Anticancer Res. 2017;37:2721-2725.
    PubMed     Text format     Abstract available


  123. SHOJI F, Toyokawa G, Harada N, Itoh S, et al
    Surgical Treatment and Outcome of Patients with De Novo Lung Cancer After Liver Transplantation.
    Anticancer Res. 2017;37:2619-2623.
    PubMed     Text format     Abstract available


  124. JANSSEN S, VAN Oorschot B, Kasmann L, Schild SE, et al
    Validation of a Score Developed to Estimate the 6-month Survival of Patients Treated with Palliative Local Radiotherapy for Advanced Lung Cancer.
    Anticancer Res. 2017;37:2537-2540.
    PubMed     Text format     Abstract available


  125. LIU D, Nakashima N, Nakano J, Tarumi S, et al
    Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Anticancer Res. 2017;37:2501-2507.
    PubMed     Text format     Abstract available


  126. DE MARINIS F, Bidoli P, Luciani A, Amoroso D, et al
    EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:2457-2464.
    PubMed     Text format     Abstract available


  127. CHUANG CL, Wang CH, Hsu CH, Hsiao CL, et al
    Contribution of Double-strand Break Repair Gene Nijmegen Breakage Syndrome 1 Genotypes, Gender Difference and Smoking Status to Taiwanese Lung Cancer.
    Anticancer Res. 2017;37:2417-2423.
    PubMed     Text format     Abstract available


  128. LEE AY, Kim S, Lee S, Jiang HL, et al
    Knockdown of Importin 7 Inhibits Lung Tumorigenesis in K-rasLA1 Lung Cancer Mice.
    Anticancer Res. 2017;37:2381-2386.
    PubMed     Text format     Abstract available


  129. MASAGO K, Fujita S, Hata A, Okuda C, et al
    PD-L1 Expression in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:2269-2274.
    PubMed     Text format     Abstract available


  130. HAO C, Cui Y, Hu MU, Zhi X, et al
    OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:2245-2254.
    PubMed     Text format     Abstract available


  131. TOKUNAGA S, Nagano T, Kobayashi K, Katsurada M, et al
    Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells.
    Anticancer Res. 2017;37:2225-2231.
    PubMed     Text format     Abstract available


  132. AKAMINE T, Toyokawa G, Matsubara T, Kozuma Y, et al
    Significance of the Preoperative CONUT Score in Predicting Postoperative Disease-free and Overall Survival in Patients with Lung Adenocarcinoma with Obstructive Lung Disease.
    Anticancer Res. 2017;37:2735-2742.
    PubMed     Text format     Abstract available


  133. JINGU K, Matsuo Y, Onishi H, Yamamoto T, et al
    Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:2709-2713.
    PubMed     Text format     Abstract available


  134. MIYATA T, Oyama T, Yoshimatsu T, Higa H, et al
    The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma.
    Anticancer Res. 2017;37:2541-2547.
    PubMed     Text format     Abstract available


  135. DORE-SAVARD L, Chen Z, Winnard PT Jr, Krishnamachary B, et al
    Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme.
    Anticancer Res. 2017;37:2195-2200.
    PubMed     Text format     Abstract available


    April 2017
  136. TSOUKALAS N, Aravantinou-Fatorou E, Tolia M, Giaginis C, et al
    Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1773-1778.
    PubMed     Text format     Abstract available


  137. OKAMOTO T, Kohno M, Ito K, Takada K, et al
    Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
    Anticancer Res. 2017;37:1729-1735.
    PubMed     Text format     Abstract available


  138. KAITO D, Iihara H, Funaguchi N, Endo J, et al
    Efficacy of Single-dose First-generation 5-HT3 Receptor Antagonist and Dexamethasone for Preventing Nausea and Vomiting Induced by Low-dose Carboplatin-based Chemotherapy.
    Anticancer Res. 2017;37:1965-1970.
    PubMed     Text format     Abstract available


  139. ABE S, Yamashita SI, Miyahara SO, Wakahara J, et al
    Prognostic Significance of BMI-1 But Not MEL-18 Expression in Pulmonary Squamous Cell Carcinoma.
    Anticancer Res. 2017;37:1923-1929.
    PubMed     Text format     Abstract available


    March 2017
  140. KASMANN L, Bolm L, Janssen S, Rades D, et al
    Prognostic Factors and Treatment of Early-stage Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1535-1537.
    PubMed     Text format     Abstract available


  141. YOH K, Goto Y, Naito Y, Kishi K, et al
    Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.
    Anticancer Res. 2017;37:1507-1513.
    PubMed     Text format     Abstract available


  142. TOYOKAWA G, Takada K, Okamoto T, Kozuma Y, et al
    Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:1393-1401.
    PubMed     Text format     Abstract available


  143. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


  144. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer.
    Anticancer Res. 2017;37:1413-1416.
    PubMed     Text format     Abstract available


  145. BATTOLLA E, Canessa PA, Ferro P, Franceschini MC, et al
    Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Anticancer Res. 2017;37:1387-1391.
    PubMed     Text format     Abstract available


    February 2017
  146. SONE K, Oguri T, Nakao M, Kagawa Y, et al
    CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
    Anticancer Res. 2017;37:935-939.
    PubMed     Text format     Abstract available


  147. YAMASAKI M, Murakami I, Nakano K, Doi M, et al
    Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:923-928.
    PubMed     Text format     Abstract available


  148. TOYOKAWA G, Kozuma Y, Matsubara T, Haratake N, et al
    Radiological Features of the Surgically Resected Small-sized Small-cell Lung Cancer on Computed Tomography.
    Anticancer Res. 2017;37:877-881.
    PubMed     Text format     Abstract available


  149. TAKEDA K, Yamasaki A, Igishi T, Kawasaki Y, et al
    Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema.
    Anticancer Res. 2017;37:765-771.
    PubMed     Text format     Abstract available


  150. SHOJI F, Haratake N, Akamine T, Takamori S, et al
    The Preoperative Controlling Nutritional Status Score Predicts Survival After Curative Surgery in Patients with Pathological Stage I Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:741-747.
    PubMed     Text format     Abstract available


  151. ISHIKURA N, Yanagisawa M, Noguchi-Sasaki M, Iwai T, et al
    Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
    Anticancer Res. 2017;37:623-629.
    PubMed     Text format     Abstract available


  152. SIRIMANGKALAKITTI N, Chamni S, Suwanborirux K, Chanvorachote P, et al
    Renieramycin M Attenuates Cancer Stem Cell-like Phenotypes in H460 Lung Cancer Cells.
    Anticancer Res. 2017;37:615-621.
    PubMed     Text format     Abstract available


  153. RAFEI H, El-Bahesh E, Finianos A, Nassereddine S, et al
    Immune-based Therapies for Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:377-387.
    PubMed     Text format     Abstract available


  154. TANDBERG DJ, Holt T, Kelsey CR
    Plasma Metabolites and Risk of Radiation-induced Esophagitis: A Secondary Analysis from a Prospective Study.
    Anticancer Res. 2017;37:719-725.
    PubMed     Text format     Abstract available


  155. LIM YS, Cha W, Park MW, Jeong WJ, et al
    HIF1alpha in Tumorigenesis of Adenoid Cystic Carcinoma.
    Anticancer Res. 2017;37:599-606.
    PubMed     Text format     Abstract available


    January 2017
  156. CHUDASAMA D, Barr J, Beeson J, Beddows E, et al
    Detection of Circulating Tumour Cells and Survival of Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:169-173.
    PubMed     Text format     Abstract available


  157. SUZAWA K, Shien K, Peng H, Sakaguchi M, et al
    Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies.
    Anticancer Res. 2017;37:301-307.
    PubMed     Text format     Abstract available


  158. FUJIYOSHI K, Yamamoto G, Takenoya T, Takahashi A, et al
    Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Anticancer Res. 2017;37:239-247.
    PubMed     Text format     Abstract available


  159. YURUGI Y, Wakahara M, Matsuoka Y, Sakabe T, et al
    Podoplanin Expression in Cancer-associated Fibroblasts Predicts Poor Prognosis in Patients with Squamous Cell Carcinoma of the Lung.
    Anticancer Res. 2017;37:207-213.
    PubMed     Text format     Abstract available


  160. PASQUALETTI F, Montrone S, Vivaldi C, Zani M, et al
    Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:315-319.
    PubMed     Text format     Abstract available


  161. YANO S, Takehara K, Kishimoto H, Tazawa H, et al
    Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models.
    Anticancer Res. 2017;37:57-60.
    PubMed     Text format     Abstract available


    December 2016
  162. ISLA D, Felip E, Vinolas N, Provencio M, et al
    Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07.
    Anticancer Res. 2016;36:6647-6653.
    PubMed     Text format     Abstract available


  163. KAIRA K, Higuchi T, Sunaga N, Arisaka Y, et al
    Usefulness of 18F-alpha-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer.
    Anticancer Res. 2016;36:6481-6490.
    PubMed     Text format     Abstract available


  164. PINKHIEN T, Maiuthed A, Chamni S, Suwanborirux K, et al
    Bishydroquinone Renieramycin M Induces Apoptosis of Human Lung Cancer Cells Through a Mitochondria-dependent Pathway.
    Anticancer Res. 2016;36:6327-6333.
    PubMed     Text format     Abstract available


  165. YOSHIDA T, Okamoto T, Yano T, Takada K, et al
    Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:6319-6326.
    PubMed     Text format     Abstract available


  166. GRIDELLI C, Chella A, Valmadre G, Allegrini G, et al
    Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.
    Anticancer Res. 2016;36:6535-6540.
    PubMed     Text format     Abstract available


  167. CHECK JH, Check D, Wilson C, Lofberg P, et al
    Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer.
    Anticancer Res. 2016;36:6511-6513.
    PubMed     Text format     Abstract available


  168. SUNDARAM S, Yan L
    High-fat Diet Enhances Mammary Tumorigenesis and Pulmonary Metastasis and Alters Inflammatory and Angiogenic Profiles in MMTV-PyMT Mice.
    Anticancer Res. 2016;36:6279-6287.
    PubMed     Text format     Abstract available


  169. OKAZAKI I, Ishikawa S, Ando W, Sohara Y, et al
    Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens.
    Anticancer Res. 2016;36:6207-6224.
    PubMed     Text format     Abstract available


    November 2016
  170. HSIA TC, Yu CC, Hsiao YT, Wu SH, et al
    Cantharidin Impairs Cell Migration and Invasion of Human Lung Cancer NCI-H460 Cells via UPA and MAPK Signaling Pathways.
    Anticancer Res. 2016;36:5989-5997.
    PubMed     Text format     Abstract available


  171. YASUKAWA M, Nakazawa T, Kawaguchi T, Kawai N, et al
    Minodronic Acid in Combination with gammadeltaT Cells Induces Apoptosis of Non-small Cell Lung Carcinoma Cell Lines.
    Anticancer Res. 2016;36:5883-5886.
    PubMed     Text format     Abstract available


  172. CHANVORACHOTE P, Chamni S, Ninsontia C, Phiboonchaiyanan PP, et al
    Potential Anti-metastasis Natural Compounds for Lung Cancer.
    Anticancer Res. 2016;36:5707-5717.
    PubMed     Text format     Abstract available


  173. WATARAI H, Okada M, Kuramoto K, Takeda H, et al
    Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin.
    Anticancer Res. 2016;36:6083-6092.
    PubMed     Text format     Abstract available


  174. YE X, Zhou Q, Matsumoto Y, Moriyama M, et al
    Inhibition of Glutaminolysis Inhibits Cell Growth via Down-regulating Mtorc1 Signaling in Lung Squamous Cell Carcinoma.
    Anticancer Res. 2016;36:6021-6029.
    PubMed     Text format     Abstract available


  175. AMBROSIO R, Ombra MN, Gridelli C, Picariello G, et al
    Isoflavone Extracts Enhance the Effect of Epidermal Growth Factor Receptor Inhibitors in NSCLC Cell Lines.
    Anticancer Res. 2016;36:5827-5833.
    PubMed     Text format     Abstract available


    October 2016
  176. KARZIJN R, Alberts L, Kelder JC, Hofman FN, et al
    Post-treatment Surveillance for Stage I and II Non-small Cell Lung Cancer: Impact on Clinical Outcome.
    Anticancer Res. 2016;36:5413-5418.
    PubMed     Text format     Abstract available


  177. KOYI H, Hillerdal G, Kolbeck KG, Brodin D, et al
    Non-small Cell Lung Cancer (NSCLC) in Octogenarians in Clinical Practice.
    Anticancer Res. 2016;36:5397-5402.
    PubMed     Text format     Abstract available


  178. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available


  179. MAEBAYASHI T, Ishibashi N, Aizawa T, Sakaguchi M, et al
    Radiation Pneumonitis Changes over Time after Stereotactic Body Radiation Therapy for Lung Tumors: Post-treatment Cavity (Sunny-side-up Egg-like) Changes.
    Anticancer Res. 2016;36:5563-5570.
    PubMed     Text format     Abstract available


    September 2016
  180. INOMATA M, Shimokawa K, Tokui K, Taka C, et al
    Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:4951-4.
    PubMed     Text format     Abstract available


  181. SCHMID S, LE UT, Haager B, Mayer O, et al
    Local Concentrations of CC-Chemokine-Ligand 18 Correlate with Tumor Size in Non-small Cell Lung Cancer and Are Elevated in Lymph Node-positive Disease.
    Anticancer Res. 2016;36:4667-71.
    PubMed     Text format     Abstract available


  182. MATSUOKA Y, Yurugi Y, Takagi Y, Wakahara M, et al
    Prognostic Significance of Solid and Micropapillary Components in Invasive Lung Adenocarcinomas Measuring </=3 cm.
    Anticancer Res. 2016;36:4923-30.
    PubMed     Text format     Abstract available


  183. TOYOKAWA G, Taguchi K, Edagawa M, Shimamatsu S, et al
    The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
    Anticancer Res. 2016;36:4841-6.
    PubMed     Text format     Abstract available


  184. VAN DER MEER FS, Schramel FM, VAN Vulpen M, El Sharouni SY, et al
    Feasibility of Concomitant Chemoradiotherapy in Daily Practice for Patients with NSCLC Stage III.
    Anticancer Res. 2016;36:4673-6.
    PubMed     Text format     Abstract available


    August 2016
  185. TOYOKAWA G, Takada K, Haratake N, Takamori S, et al
    Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer.
    Anticancer Res. 2016;36:4329-36.
    PubMed     Text format     Abstract available


  186. OOI H, Chen CY, Hsiao YC, Huang WS, et al
    Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis.
    Anticancer Res. 2016;36:4313-20.
    PubMed     Text format     Abstract available


  187. DAVIES RS, Nelmes DJ, Butler R, Lester JF, et al
    Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different?
    Anticancer Res. 2016;36:4267-71.
    PubMed     Text format     Abstract available


  188. KASMANN L, Janssen S, Rades D
    Karnofsky Performance Score, Radiation Dose and Nodal Status Predict Survival of Elderly Patients Irradiated for Limited-disease Small-cell Lung Cancer.
    Anticancer Res. 2016;36:4177-80.
    PubMed     Text format     Abstract available


  189. SILVONIEMI M, Vasankari T, Loyttyniemi E, Valtonen M, et al
    Symptom Assessment for Patients with Non-small Cell Lung Cancer Scheduled for Chemotherapy.
    Anticancer Res. 2016;36:4123-8.
    PubMed     Text format     Abstract available



  190. Advances in Respiratory Cancerogenesis.
    Anticancer Res. 2016;36:4376.
    PubMed     Text format    


  191. URAMOTO H, Nakajima Y, Kinoshita H, Akiyama H, et al
    Equivalent Outcome of Patients with Locally Advanced NSCLC Treated with Salvage Surgery Compared to Induction Chemotherapy Followed by Surgical Resection.
    Anticancer Res. 2016;36:4243-7.
    PubMed     Text format     Abstract available


  192. MAYS AC, Feng X, Browne JD, Sullivan CA, et al
    Chemokine and Chemokine Receptor Profiles in Metastatic Salivary Adenoid Cystic Carcinoma.
    Anticancer Res. 2016;36:4013-8.
    PubMed     Text format     Abstract available


  193. TOME Y, Yano S, Sugimoto N, Mii S, et al
    Use of alphav Integrin Linked to Green Fluorescent Protein in Osteosarcoma Cells and Confocal Microscopy to Image Molecular Dynamics During Lung Metastasis in Nude Mice.
    Anticancer Res. 2016;36:3811-6.
    PubMed     Text format     Abstract available


    July 2016
  194. INUI T, Amitani H, Kubo K, Kuchiike D, et al
    Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
    Anticancer Res. 2016;36:3767-70.
    PubMed     Text format     Abstract available


  195. YAMASHITA K, Hasegawa H, Fujita M, Nishi M, et al
    Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer.
    Anticancer Res. 2016;36:3659-65.
    PubMed     Text format     Abstract available


  196. KASMANN L, Janssen S, Rades D
    Prognostic Factors Including the Expression of Thyroid Transcription Factor 1 (TTF1) in Patients Irradiated for Limited-disease Small Cell Lung Cancer.
    Anticancer Res. 2016;36:3499-503.
    PubMed     Text format     Abstract available


  197. TAKADA K, Toyokawa G, Okamoto T, Akamine T, et al
    An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
    Anticancer Res. 2016;36:3409-12.
    PubMed     Text format     Abstract available


  198. HOLZER TR, Fulford AD, Reising LO, Nedderman DM, et al
    Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma.
    Anticancer Res. 2016;36:3277-88.
    PubMed     Text format     Abstract available


  199. OISHI S, Kudaka W, Toita T, Ariga T, et al
    Prognostic Factors and Treatment Outcome for Patients with Stage IVB Cervical Cancer.
    Anticancer Res. 2016;36:3471-5.
    PubMed     Text format     Abstract available


  200. MATSUI T, Nagata N, Hirata K, Okazaki S, et al
    Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.
    Anticancer Res. 2016;36:3437-43.
    PubMed     Text format     Abstract available


    June 2016
  201. TAMIYA M, Tamiya A, Yasue T, Nakao K, et al
    Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
    Anticancer Res. 2016;36:2939-44.
    PubMed     Text format     Abstract available


  202. YAMADA K, Azuma K, Takeshita M, Uchino J, et al
    Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
    Anticancer Res. 2016;36:2881-7.
    PubMed     Text format     Abstract available


  203. OKAMOTO T, Kitahara H, Shimamatsu S, Katsura M, et al
    Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.
    Anticancer Res. 2016;36:3057-63.
    PubMed     Text format     Abstract available


    May 2016
  204. URAMOTO H, Iijima Y, Nakajima Y, Kinoshita H, et al
    Accurate Diagnosis of Aortic Invasion in Patients with Lung Cancer.
    Anticancer Res. 2016;36:2391-5.
    PubMed     Text format     Abstract available


  205. URAMOTO H, Nakajima Y, Kinoshita H
    Is the Isolated Pericardial Fat Pad Sufficient to Cover the Bronchial Stump and Separate the Pulmonary Artery in Order to Prevent Bronchopleural Fistula in Patients with Lung Cancer?
    Anticancer Res. 2016;36:2385-9.
    PubMed     Text format     Abstract available


  206. NICOS M, Krawczyk P, Powrozek T, Szudy P, et al
    PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:2243-9.
    PubMed     Text format     Abstract available


  207. SU JM, Hsu YY, Lin P, Chang H, et al
    Nuclear Accumulation of Heat-shock Protein 90 Is Associated with Poor Survival and Metastasis in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:2197-203.
    PubMed     Text format     Abstract available


  208. ROCCO G, Petitti T, Martucci N, Piccirillo MC, et al
    Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern Italy.
    Anticancer Res. 2016;36:2119-24.
    PubMed     Text format     Abstract available


  209. FIALA O, Pesek M, Finek J, Topolcan O, et al
    Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.
    Anticancer Res. 2016;36:2459-65.
    PubMed     Text format     Abstract available


  210. UGURLUER G, Chang K, Gamez ME, Arnett AL, et al
    Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
    Anticancer Res. 2016;36:2331-8.
    PubMed     Text format     Abstract available


    April 2016

  211. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management.
    Anticancer Res. 2016;36:2049.
    PubMed     Text format    



  212. Lung Cancer and Personalized Medicine. Current Knowledge and Therapies.
    Anticancer Res. 2016;36:2049.
    PubMed     Text format    


  213. JANSSEN S, Kaesmann L, Schild SE, Rades D, et al
    Impact of the Radiation Dose and Completion of Palliative Radiotherapy on Survival in Patients Treated for Locally Advanced Lung Cancer.
    Anticancer Res. 2016;36:1825-8.
    PubMed     Text format     Abstract available


  214. KIMURA T, Taniguchi H, Watanabe N, Saka H, et al
    Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.
    Anticancer Res. 2016;36:1767-71.
    PubMed     Text format     Abstract available


  215. KESHTGARPOUR M, Tan WS, Zwanziger J, Awadalla S, et al
    Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.
    Anticancer Res. 2016;36:1759-65.
    PubMed     Text format     Abstract available


  216. SIRIMANGKALAKITTI N, Chamni S, Suwanborirux K, Chanvorachote P, et al
    Renieramycin M Sensitizes Anoikis-resistant H460 Lung Cancer Cells to Anoikis.
    Anticancer Res. 2016;36:1665-71.
    PubMed     Text format     Abstract available


  217. BAZIN MA, Rousseau B, Marhadour S, Tomasoni C, et al
    Discovery of Novel (Imidazo[1,2-a]pyrazin-6-yl)ureas as Antiproliferative Agents Targeting P53 in Non-small Cell Lung Cancer Cell Lines.
    Anticancer Res. 2016;36:1621-30.
    PubMed     Text format     Abstract available


  218. TADOKORO A, Kanaji N, Liu D, Yokomise H, et al
    Vimentin Regulates Invasiveness and Is a Poor Prognostic Marker in Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:1545-51.
    PubMed     Text format     Abstract available


  219. GEBAUER F, Wicklein D, Tachezy M, Grob T, et al
    Establishment and Characterization of a Pair of Patient-derived Human Non-small Cell Lung Cancer Cell Lines from a Primary Tumor and Corresponding Lymph Node Metastasis.
    Anticancer Res. 2016;36:1507-18.
    PubMed     Text format     Abstract available


  220. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Anticancer Res. 2016;36:1973-8.
    PubMed     Text format     Abstract available


  221. NISMAN B, Appelbaum L, Yutkin V, Nechushtan H, et al
    Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver.
    Anticancer Res. 2016;36:1791-7.
    PubMed     Text format     Abstract available


    March 2016
  222. KASMANN L, Janssen S, Schild SE, Rades D, et al
    Impact of the Radiation Dose on Survival after Radiochemotherapy for Small-cell Lung Cancer.
    Anticancer Res. 2016;36:1089-91.
    PubMed     Text format     Abstract available


  223. OWEN S, Gao Y, Zhi X, Wei C, et al
    Effect of YangZheng XiaoJi Extract, DME-25, on Endothelial Cells and their Response to Avastin.
    Anticancer Res. 2016;36:1181-92.
    PubMed     Text format     Abstract available


  224. SVATON M, Fiala O, Pesek M, Bortlicek Z, et al
    The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
    Anticancer Res. 2016;36:1077-82.
    PubMed     Text format     Abstract available


  225. KATO K, Gemba K, Fujimoto N, Aoe K, et al
    Computed Tomographic Features of Malignant Peritoneal Mesothelioma.
    Anticancer Res. 2016;36:1067-72.
    PubMed     Text format     Abstract available


    February 2016
  226. JANSSEN S, Kasmann L, Rudat V, Rades D, et al
    Stereotactic Body Radiation Therapy (SBRT) for Recurrent Non-small Cell Lung Cancer (NSCLC).
    Anticancer Res. 2016;36:825-8.
    PubMed     Text format     Abstract available


  227. KASMANN L, Janssen S, Schild SE, Rades D, et al
    Karnosky Performance Score and Radiation Dose Predict Survival of Patients Re-irradiated for a Locoregional Recurrence of Small Cell Lung Cancer.
    Anticancer Res. 2016;36:803-5.
    PubMed     Text format     Abstract available


  228. YOSHIYAMA A, Morii T, Ohtsuka K, Ohnishi H, et al
    Development of Stemness in Cancer Cell Lines Resistant to the Anticancer Effects of Zoledronic Acid.
    Anticancer Res. 2016;36:625-31.
    PubMed     Text format     Abstract available


  229. KUCERA R, Topolcan O, Fiala O, Kinkorova J, et al
    The Role of TPS and TPA in the Diagnostics of Distant Metastases.
    Anticancer Res. 2016;36:773-7.
    PubMed     Text format     Abstract available


    January 2016
  230. SHI R, Diaz R, Shi Z, Duvall E, et al
    The Effect of Payer Status on Survival of Patients with Stage I/II Non-small Cell Lung Cancer: NCDB 1998-2011.
    Anticancer Res. 2016;36:319-26.
    PubMed     Text format     Abstract available


  231. KUBOTA T, Okano Y, Sakai M, Takaoka M, et al
    Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer.
    Anticancer Res. 2016;36:307-12.
    PubMed     Text format     Abstract available


  232. PARK HJ, Oh JS, Chang JW, Hwang SG, et al
    Proton Irradiation Sensitizes Radioresistant Non-small Cell Lung Cancer Cells by Modulating Epidermal Growth Factor Receptor-mediated DNA Repair.
    Anticancer Res. 2016;36:205-12.
    PubMed     Text format     Abstract available


  233. LAI CY, Chang WS, Hsieh YH, Hsu CM, et al
    Association of Tissue Inhibitor of Metalloproteinase-1 Genotypes with Lung Cancer Risk in Taiwan.
    Anticancer Res. 2016;36:155-160.
    PubMed     Text format     Abstract available


  234. CHIKAISHI Y, Uramoto H, Koyanagi Y, Yamada S, et al
    TMPRSS4 Expression as a Marker of Recurrence in Patients with Lung Cancer.
    Anticancer Res. 2016;36:121-7.
    PubMed     Text format     Abstract available


  235. KIMURA Y, Sumiyoshi M, Baba K
    Antitumor and Antimetastatic Activity of Synthetic Hydroxystilbenes Through Inhibition of Lymphangiogenesis and M2 Macrophage Differentiation of Tumor-associated Macrophages.
    Anticancer Res. 2016;36:137-48.
    PubMed     Text format     Abstract available


  236. LUMACHI F, Chiara GB, Tozzoli R, Del Contea A, et al
    Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis.
    Anticancer Res. 2016;36:13-9.
    PubMed     Text format     Abstract available


  237. DEVINE A, Marignol L
    Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis.
    Anticancer Res. 2016;36:5-12.
    PubMed     Text format     Abstract available


  238. FIALA O, Pesek M, Finek J, Svaton M, et al
    Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.
    Anticancer Res. 2016;36:461-6.
    PubMed     Text format     Abstract available


  239. FIALA O, Pesek M, Finek J, Minarik M, et al
    Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.
    Anticancer Res. 2016;36:455-60.
    PubMed     Text format     Abstract available


  240. FIALA O, Pesek M, Finek J, Svaton M, et al
    Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene.
    Anticancer Res. 2016;36:447-53.
    PubMed     Text format     Abstract available


    December 2015
  241. SPAKS A, Jaunalksne I, Spaka I, Chudasama D, et al
    Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung Cancer.
    Anticancer Res. 2015;35:6979-83.
    PubMed     Text format     Abstract available


  242. WATANABE S, Inoue A, Nukiwa T, Kobayashi K, et al
    Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
    Anticancer Res. 2015;35:6957-61.
    PubMed     Text format     Abstract available


  243. ALBERTS L, El Sharouni SY, Hofman FN, VAN Putte BP, et al
    Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts.
    Anticancer Res. 2015;35:6773-9.
    PubMed     Text format     Abstract available


    November 2015
  244. GOKE A, Goke R, Ofner A, Herbst A, et al
    The FGFR Inhibitor NVP-BGJ398 Induces NSCLC Cell Death by Activating Caspase-dependent Pathways as well as Caspase-independent Apoptosis.
    Anticancer Res. 2015;35:5873-9.
    PubMed     Text format     Abstract available


  245. YOSHIMASU T, Ohashi T, Oura S, Kokawa Y, et al
    A Theoretical Model for the Hormetic Dose-response Curve for Anticancer Agents.
    Anticancer Res. 2015;35:5851-5.
    PubMed     Text format     Abstract available


  246. DEMPKE WC, Edvardsen K, Lu S, Reinmuth N, et al
    Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Anticancer Res. 2015;35:5797-806.
    PubMed     Text format     Abstract available


  247. DEMPKE WC, Sellmann L, Fenchel K, Edvardsen K, et al
    Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Anticancer Res. 2015;35:5745-57.
    PubMed     Text format     Abstract available


  248. GALLO K, Brickman A, Warren WH, Gattuso P, et al
    Unresectable Middle Mediastinal Biphasic Pulmonary Blastoma.
    Anticancer Res. 2015;35:6325-7.
    PubMed     Text format     Abstract available


  249. MICHELSEN L, Sorensen JB
    Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Anticancer Res. 2015;35:6255-9.
    PubMed     Text format     Abstract available


  250. ANDERSEN M, Trapani D, Ravn J, Sorensen JB, et al
    Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Anticancer Res. 2015;35:6223-9.
    PubMed     Text format     Abstract available


  251. KLAIRMONT M, Kopkash K, Favuzza J, Hill M, et al
    Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus.
    Anticancer Res. 2015;35:6159-62.
    PubMed     Text format     Abstract available


    October 2015
  252. KASTELIJN EA, El Sharouni SY, Hofman FN, Van Putte BP, et al
    Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection.
    Anticancer Res. 2015;35:5607-14.
    PubMed     Text format     Abstract available


  253. FRAKULLI R, Salvi F, Balestrini D, Parisi A, et al
    Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas.
    Anticancer Res. 2015;35:5581-6.
    PubMed     Text format     Abstract available


  254. WIEGAND S, Zimmermann A, Wilhelm T, Werner JA, et al
    Survival After Distant Metastasis in Head and Neck Cancer.
    Anticancer Res. 2015;35:5499-502.
    PubMed     Text format     Abstract available


  255. VETVICKA V, Vetvickova J
    Glucan Supplementation Has Strong Anti-melanoma Effects: Role of NK Cells.
    Anticancer Res. 2015;35:5287-92.
    PubMed     Text format     Abstract available


  256. KUNII E, Ozasa H, Oguri T, Maeno K, et al
    Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115.
    Anticancer Res. 2015;35:5241-7.
    PubMed     Text format     Abstract available


  257. FERGUSON DM, Jacobson BA, Jay-Dixon J, Patel MR, et al
    Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
    Anticancer Res. 2015;35:5211-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: